Eptacog Alfa Biosimilar(Aryogen Pharmed)

N/A

Report date: 2023/11/21 20:03:29

Base Information

Drug NameEptacog Alfa Biosimilar(Aryogen Pharmed)
Drug Alias NameFactor VIII, recombinant human with Fc fusion(Aryogen Pharmed)rFVIII-Fc(Aryogen Pharmed)AryoSeven
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant coagulation factorBiologics > Biosimilar
Mechanisms of ActionFactor VIIa replacementsBlood coagulation pathway activationCoagulation factor X stimulants +[4] 
TargetsCoagulation factor XCoagulation factor IX
Therapy Area/IndicationsHemophilia AFactor VII Deficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIran
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAryogen Pharmed Co
China Registration ClassN/A

Develop Information

Active CompaniesAryogen Pharmed Co
Inactive CompaniesN/A
Active IndicationsHemophilia A
Inactive IndicationsFactor VII Deficiency

Other Information

ATC CodeN/A
Related LinksN/A